# A Prospective Clinical Study to Evaluate the Safety and Effectiveness of Pulmonary Vein Isolation Plus Box Isolation of Fibrotic Areas With the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation

Study · id `cardio:ct-nct06973031` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06973031](<https://clinicaltrials.gov/study/NCT06973031>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06973031

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 115 participants.

## Technical summary

Registry record NCT06973031. Allocation not applicable; no masking; primary purpose treatment. Start 2025-06-10 (actual); primary completion 2028-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 115 participants (planned count; ClinicalTrials.gov record NCT06973031, source copy `cardio:ctgov-nct06973031-2025-06-16`, retrieved 2026-10-26)
- Started: 2025-06-10 (actual) (ClinicalTrials.gov record NCT06973031, source copy `cardio:ctgov-nct06973031-2025-06-16`, retrieved 2026-10-26)
- Primary completion: 2028-06 (anticipated) (ClinicalTrials.gov record NCT06973031, source copy `cardio:ctgov-nct06973031-2025-06-16`, retrieved 2026-10-26)
- Completion: 2028-06 (anticipated) (ClinicalTrials.gov record NCT06973031, source copy `cardio:ctgov-nct06973031-2025-06-16`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT06973031, source copy `cardio:ctgov-nct06973031-2025-06-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06973031-2025-06-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Prospective Clinical Study to Evaluate the Safety and Effectiveness of Pulmonary Vein Isolation Plus Box Isolation of Fibrotic Areas With the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation
- Acronym: GLOBAL-PF
- Condition: Paroxysmal Atrial Fibrillation (PAF)
- Condition: Persistent Atrial Fibrillation
- Intervention (Device): Globe Pulsed Field System
- Lead sponsor: Kardium Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Kardium Inc. (`cardio:org-kardium-inc`)

## Provenance

Content hash: d502ab3188edf95032000f55d353340786918ebef3710362c6fb69ef8f6a8210
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
